HK1247200A1 - 酰基硫脲化合物的甲磺酸鹽及其晶體、以及它們的製造方法 - Google Patents

酰基硫脲化合物的甲磺酸鹽及其晶體、以及它們的製造方法

Info

Publication number
HK1247200A1
HK1247200A1 HK18106763.2A HK18106763A HK1247200A1 HK 1247200 A1 HK1247200 A1 HK 1247200A1 HK 18106763 A HK18106763 A HK 18106763A HK 1247200 A1 HK1247200 A1 HK 1247200A1
Authority
HK
Hong Kong
Prior art keywords
crystal
acid salt
production processes
mesylic acid
processes therefor
Prior art date
Application number
HK18106763.2A
Other languages
English (en)
Inventor
佐藤文子
Original Assignee
大鵬藥品工業株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大鵬藥品工業株式會社 filed Critical 大鵬藥品工業株式會社
Publication of HK1247200A1 publication Critical patent/HK1247200A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
HK18106763.2A 2015-04-30 2018-05-24 酰基硫脲化合物的甲磺酸鹽及其晶體、以及它們的製造方法 HK1247200A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015092815 2015-04-30
PCT/JP2016/063413 WO2016175305A1 (ja) 2015-04-30 2016-04-28 アシルチオウレア化合物のメシル酸塩及びその結晶並びにそれらの製造方法

Publications (1)

Publication Number Publication Date
HK1247200A1 true HK1247200A1 (zh) 2018-09-21

Family

ID=57199144

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106763.2A HK1247200A1 (zh) 2015-04-30 2018-05-24 酰基硫脲化合物的甲磺酸鹽及其晶體、以及它們的製造方法

Country Status (11)

Country Link
US (1) US10143688B2 (zh)
EP (1) EP3290405B1 (zh)
JP (1) JP6676626B2 (zh)
CN (1) CN107614489B (zh)
DK (1) DK3290405T3 (zh)
ES (1) ES2863586T3 (zh)
HK (1) HK1247200A1 (zh)
HU (1) HUE054405T2 (zh)
PL (1) PL3290405T3 (zh)
PT (1) PT3290405T (zh)
WO (1) WO2016175305A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3583943A4 (en) 2017-02-15 2020-12-30 Taiho Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION
EP3682882A4 (en) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co., Ltd. ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
MA53667A (fr) 2018-09-18 2021-07-28 Taiho Pharmaceutical Co Ltd Polythérapie associant un composé d'acylthiourée et de l'abiratérone
TW202140426A (zh) * 2020-02-14 2021-11-01 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2287155T3 (pl) 2008-04-10 2013-12-31 Taiho Pharmaceutical Co Ltd Acylotiomocznik lub jego sól oraz jego zastosowanie
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
US9149471B2 (en) * 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis

Also Published As

Publication number Publication date
DK3290405T3 (da) 2021-03-22
US20180161317A1 (en) 2018-06-14
WO2016175305A1 (ja) 2016-11-03
ES2863586T3 (es) 2021-10-11
US10143688B2 (en) 2018-12-04
HUE054405T2 (hu) 2021-09-28
EP3290405A4 (en) 2018-09-12
JP6676626B2 (ja) 2020-04-08
JPWO2016175305A1 (ja) 2018-04-12
EP3290405B1 (en) 2021-02-17
PL3290405T3 (pl) 2021-07-12
EP3290405A1 (en) 2018-03-07
PT3290405T (pt) 2021-03-23
CN107614489A (zh) 2018-01-19
CN107614489B (zh) 2021-05-11

Similar Documents

Publication Publication Date Title
IL262138A (en) Cell-free production of ribonucleic acid
HK1245762A1 (zh) 丙烯酸生產方法
GB2550003B (en) Process for the production of formaldehyde-stabilised urea
IL249415A0 (en) Electrolytic production of ammonia
IL254413A0 (en) Cell-free ribonucleic acid production
HK1258002A1 (zh) 羧基化的納米纖維素的生產
EP3315827A4 (en) Process for production of gaskets
HK1247200A1 (zh) 酰基硫脲化合物的甲磺酸鹽及其晶體、以及它們的製造方法
EP3341405A4 (en) PROCESS FOR INSULIN PRODUCTION
GB201516516D0 (en) Process of manufacture
EP3414256A4 (en) AMINO SALT OF OBETICHOLIC ACID
HUP1700197A2 (en) Industrial procedure for production of cariprazine
HUE053858T2 (hu) Eljárás diének elõállítására
GB201518792D0 (en) Production of proteins
ZA201701003B (en) Process for the production of a pgm-enriched alloy
FI20146056A (fi) Menetelmä litiummetallifosfaattien tuottamiseksi
DK3200779T3 (en) Novel anthranilic acid derivatives
ZA201801991B (en) Process for the preparation of monochloroacetic acid
ZA201800909B (en) Process for the recovery of hydrochloric acid
PL3271325T3 (pl) Sposób wytwarzania (S)-metolachloru
GB201416909D0 (en) Method of forming concentrated solution
GB2555726B (en) Urea production method
GB201700973D0 (en) Process of manufacture
PL3362424T3 (pl) Wytwarzanie związków alkiloaromatycznych
PT3271325T (pt) Processo de produção de (s)-metolacloro